Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582140 · ClinicalTrials.gov registry record · Phase 1
Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00582140 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 22 participants.
The verdict
NCT00582140, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The investigators are trying to find new methods to treat prostate cancer. The approach they investigators are taking is to try to enhance patients own immune response against the cancer. In this study the investigators will be testing the safety of a vaccine that may be able to help the body fight prostate cancer.
Interventions
- BIOLOGICAL pTVG-HP with rhGM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00582140
The ClinicalTrials.gov registry entry for NCT00582140 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pTVG-HP with rhGM-CSF is the first listed.
NCT00582140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00582140 about?
NCT00582140 is a clinical study titled "Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer". The investigators are trying to find new methods to treat prostate cancer. The approach they investigators are taking is to try to enhance patients own immune response against the cancer. In this study the investigators will be testing the safety of a vaccine that may be able to help the body fight ...
What is the current status of trial NCT00582140?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2005-03. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00582140?
The interventions under investigation include: pTVG-HP with rhGM-CSF (BIOLOGICAL).
Who is sponsoring clinical trial NCT00582140?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.